Further bacteriological evaluation of virginiamycin.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001431:Bacteriological Techniques; D003013:Clostridium / Q000187:drug effects; D003470:Culture Media; D004357:Drug Synergism; D004755:Enterobacteriaceae / Q000187:drug effects*; D006190:Haemophilus / Q000187:drug effects; D007919:Leptospira / Q000187:drug effects; D008288:Malaria / Q000188:drug therapy; D051379:Mice; D008826:Microbial Sensitivity Tests; D009161:Mycobacterium / Q000187:drug effects; D010961:Plasmodium; D011528:Protozoan Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D014123:Toxoplasmosis / Q000188:drug therapy; D014244:Trichomonas / Q000187:drug effects; D014769:Virginiamycin / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D003470:Culture Media; D014769:Virginiamycin